Delving into the Latest Updates on Research Triangle Park Laboratories Inc. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

nAChR α4/β2/α5(Nicotinic acetylcholine receptor alpha4/beta2/alpha5)	1

During the last decade, combinatorial libraries have played an increasingly important role in the drug discovery process.The identification of novel lead structures has been realized by screening these collections in a wide variety of biol. assays.Library design can encompass a broad spectrum of approaches, from large sets of compounds used for general screening purposes to smaller collections of mols. that incorporate structural motifs aimed at exhibiting activity towards select biol. targets.We wish to report on the development of a polymer-bound indanol library produced for general screening purposes.The synthesis of the scaffold and the solid phase parallel approach used to generate the library will be disclosed.From this collection, we have obtained unique structural leads as potential therapeutic agents for cardiovascular, cancer, and CNS indications.The discovery of a novel highly selective partial M1 agonist from this library has led to the identification of a clin. candidate for the treatment of cognitive impairment associated with Alzheimer′s Disease.

F1000Research

The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days

Article

Author: Hemkens, Lars G ; Haber, Noah A ; Nagavci, Blin ; Appenzeller-Herzog, Christian ; Moher, David ; Axfors, Cathrine ; Sauermann, Mandy ; Schandelmaier, Stefan ; Contopoulos-Ioannidis, Despina G ; Malički, Mario ; Dirnagl, Ulrich ; Schmitt, Andreas M ; Min, Yan ; Ioannidis, Angeliki Diotima ; Danchev, Valentin ; Gartlehner, Gerald ; Ioannidis, John P A ; Speich, Benjamin ; Riedel, Nico ; Lythgoe, Mark P ; Agarwal, Arnav ; Roth, Jan A ; O'Sullivan, Jack W ; Meerpohl, Joerg J ; Janiaud, Perrine ; Ewald, Hannah ; Naudet, Florian ; Williamson, Paula R ; Van't Hooft, Janneke ; Saccilotto, Ramon ; Macleod, Malcolm ; Pauli-Magnus, Christiane ; Ma, Wenyan ; Goodman, Steven N

Background: Never before have clinical trials drawn as much public attention as those testing interventions for COVID-19. We aimed to describe the worldwide COVID-19 clinical research response and its evolution over the first 100 days of the pandemic.Methods:Descriptive analysis of planned, ongoing or completed trials by April 9, 2020 testing any intervention to treat or prevent COVID-19, systematically identified in trial registries, preprint servers, and literature databases. A survey was conducted of all trials to assess their recruitment status up to July 6, 2020.Results:Most of the 689 trials (overall target sample size 396,366) were small (median sample size 120; interquartile range [IQR] 60-300) but randomized (75.8%; n=522) and were often conducted in China (51.1%; n=352) or the USA (11%; n=76). 525 trials (76.2%) planned to include 155,571 hospitalized patients, and 25 (3.6%) planned to include 96,821 health-care workers. Treatments were evaluated in 607 trials (88.1%), frequently antivirals (n=144) or antimalarials (n=112); 78 trials (11.3%) focused on prevention, including 14 vaccine trials. No trial investigated social distancing. Interventions tested in 11 trials with >5,000 participants were also tested in 169 smaller trials (median sample size 273; IQR 90-700). Hydroxychloroquine alone was investigated in 110 trials. While 414 trials (60.0%) expected completion in 2020, only 35 trials (4.1%; 3,071 participants) were completed by July 6. Of 112 trials with detailed recruitment information, 55 had recruited <20% of the targeted sample; 27 between 20-50%; and 30 over 50% (median 14.8% [IQR 2.0-62.0%]).Conclusions:The size and speed of the COVID-19 clinical trials agenda is unprecedented. However, most trials were small investigating a small fraction of treatment options. The feasibility of this research agenda is questionable, and many trials may end in futility, wasting research resources. Much better coordination is needed to respond to global health threats.

100 Deals associated with Research Triangle Park Laboratories Inc.

Login to view more data

100 Translational Medicine associated with Research Triangle Park Laboratories Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Nicotinic acetylcholine receptor alpha4/beta2/alpha5 antagonists(Research Triangle Park Laboratories Inc.) ( nAChR α4/β2/α5 )	Nociceptive Pain More	Preclinical